Alon Altman

Professor

University of Manitoba

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Alon Altman is a faculty member at the University of Manitoba, Canada. His research primarily focuses on gynecologic oncology, emphasizing ovarian and cervical cancer treatment outcomes, surgical documentation, and the role of multidisciplinary care in cancer risk management. Recent publications include studies on treatment tolerance in older patients with ovarian cancer and the use of immune checkpoint inhibitors in metastatic endometrial cancer.

Articles (11)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Laurence Bernard

McGill University Health Centre

CANADA

View details

Frank Schweizer

University of Manitoba

CANADA

View details

Lorraine Elit

Division Head Gynecologic Oncology

Faculty of Health Sciences

CANADA

View details

Kathleen Decker

University of Manitoba

CANADA

View details

Kirk McManus

Professor

University of Manitoba

CANADA

View details

Gregg Nelson

University of Calgary

CANADA

View details

Jessica N. Hartley

CANADA

View details

Mark W. Nachtigal

CANADA

View details

Paul Cohen

University of Western Australia

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alon Altman

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Ovarian Cancer in the Older Manitoban Population—Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study

Shifting incidence and survival of epithelial ovarian cancer (1995-2014)

Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study

Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk‐reducing surgical decision‐making practices: A mixed‐methods study

A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer

Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update

Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study

Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019

The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

Collaborators (9)

Laurence Bernard

Frank Schweizer

Lorraine Elit

Kathleen Decker

Kirk McManus

Gregg Nelson

Jessica N. Hartley

Mark W. Nachtigal

Paul Cohen

Make your next move.